World Cancer Day World Cancer Day 2018
World Cancer Day 2018
In support of World Cancer Day 2018, the editors ofEMBO Press have assembled this curated collection of recently published research from across our four journals. The articles are all free to read for a limited time – we invite you to discover even more on our journal sites.
Noam Auslander, Eytan Ruppin and colleagues
A combined computational and experimental analysis reveals FUT9 as a new, context‐dependent driver of colon cancer. FUT9 expression is required in tumor initiating cells while its loss favors bulk tumor growth and supports tumor aggressiveness.
Molecular Systems Biology (2017) 13: 956
Julia Jabs, Christian Conrad and colleagues
DeathPro, an automated microscopy‐based assay resolves cell death and proliferation inhibition in 2D and 3D cultures. Drug screens using DeathPro provide insights into the impact of culture systems on drug effects and their links to genomic features.
Molecular Systems Biology (2017) 13: 955
Gabriele Picco, Enzo Medico and colleagues
In colorectal cancer (CRC), translocations of the RSPO3 gene, leading to its expression as a fusion transcript, pinpoint a therapeutically actionable mechanism of Wnt pathway activation
EMBO Molecular Medicine (2017) 9: 293-303
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Alessandra Dall’Acqua, Gustavo Baldassarre and colleagues
In epithelial ovarian cancer cells, platinum favours binding and phosphorylation of FOXO3 by the CDK6/cyclin D3 complex. FOXO3 is thus stabilized and binds the ATR promoter thereby inducing its transcription and preventing platinum‐induced cell death.
EMBO Molecular Medicine (2017) 9: 1415–1433
Metabolic stress regulates ERK activity by controlling KSR‐RAF heterodimerization
Amandine Verlande, Stjepan Uldrijan and colleagues
Amandine Verlande, Stjepan Uldrijan and colleaguesSomatic RAF/RAS mutations result in deregulated ERK signaling in melanomas. Metabolic stress impacts differently on ERK activation in BRAF- and NRAS-mutant cells, indicating that targeting of energy metabolism is not a general therapeutic strategy for melanoma.
EMBO reports (2017) e201744524
Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation
Junmei Cairns, Brooke L Fridley, Gregory D Jenkins, Yongxian Zhuang, Jia Yu, Liewei Wang
The ERBB receptor inhibitor ERRFI1 regulates AKT/EGFR signaling in an EGFR-dependent manner. In EGFR-low cells, ERRFI1 activates AKT by blocking the PHLPP-AKT interaction. In EGFR-high cells, ERRFI1 functions as a negative regulator of the EGFR pathway.
EMBO reports (2018) e44767
Whole chromosome loss and associated breakage–fusion–bridge cycles transform mouse tetraploid cells
Rozario Thomas, Daniel Henry Marks, Yvette Chin, Robert Benezra
A combination of targeted chromosome losses and breakage–fusion–bridge (BFB)–mediated genomic instability, in the context of tetraploidy, is found to be a potent driver of tumorigenesis in a mouse allograft model.
The EMBO Journal (2018) 37: 201–218
Muhammad Riaz Khan, Shaoxun Xiang, Zhiyin Song, Mian Wu
Nutrient removal from cancer cells is counterbalanced through p53‐dependent induction of pro‐survival lncRNA TRINGS and suppression of cell death signalling.
The EMBO Journal (2017) 36: 3483–3500